Full text is available at the source.
Abstract
Tirzepatide's effectiveness in real-world settings with high out-of-pocket costs remains poorly characterized.
- Persistence and adherence to tirzepatide could vary significantly in self-funded patients.
- Dose escalation patterns may differ from those observed in clinical trials.
- The impact of financial burden on treatment continuation is yet to be fully understood.
Simplified